keyword
Keywords allogeneic hematopoietic stem ...

allogeneic hematopoietic stem cell transplantation

https://read.qxmd.com/read/38523911/case-report-treatment-of-two-cases-of-recurrent-refractory-early-t-cell-precursor-acute-lymphoblastic-leukemia-with-venetoclax-combined-with-the-cag-regimen
#21
Yuxia Jiang, Lin Ji, Xin Jin, Haiying Wu, Mingxia He, Fenglin Shen, Xiaofeng Xu, Huifang Jiang
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a highly aggressive subtype of T-ALL. No standard chemotherapy regimen exists for patients with recurrent/refractory (R/R) ETP-ALL; in these patients, the primary goal of salvage therapy is to achieve remission as a foundation for consolidation and intensification treatments. This study reports cases of two patients with R/R ETP-ALL who underwent salvage therapy of venetoclax combined with the CAG regimen and achieved complete remission in the bone marrow...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38523199/sustained-remission-after-cord-blood-transplantation-for-breast-cancer-with-lung-metastases-and-myelodysplastic-syndrome
#22
JOURNAL ARTICLE
Naokazu Nakamura, Nao Yamamoto, Tadakazu Kondo, Mayumi Matsumoto, Ryo Ikunari, Tomomi Sakai, Yasuhiro Tanaka, Hiroko Tsunemine, June Takeda, Junya Kanda, Yasuhito Nannya, Seishi Ogawa, Akifumi Takaori-Kondo, Nobuyoshi Arima
Allogenic hematopoietic stem cell transplantation (allo-HSCT) is not a standard therapy for solid cancer because of its high toxicity and insufficient evidence levels. However, the potential graft-versus-solid-tumor (GVT) effect of this therapy has been discussed. Many case reports have also described treatment effects of allo-HSCT in patients with hematologic malignancies and active solid tumors. A 38-year-old woman treated with fulvestrant and abemaciclib for recurrent breast cancer with multiple lung metastases was diagnosed with myelodysplastic syndrome (MDS) with increased blasts 2...
March 25, 2024: International Journal of Hematology
https://read.qxmd.com/read/38521840/post-marketing-surveillance-of-the-safety-and-effectiveness-of-nivolumab-for-classic-hodgkin-lymphoma-in-japan
#23
JOURNAL ARTICLE
Akira Kawasaki, Kiyohiko Hatake, Itaru Matsumura, Koji Izutsu, Tomohiro Hoshino, Ayumi Akamatsu, Akito Kakuuchi, Kensei Tobinai
Nivolumab was approved for relapsed/refractory classic Hodgkin lymphoma (cHL) in Japan in 2016. After its approval, a prospective, non-interventional, observational post-marketing surveillance was initiated to evaluate the safety and effectiveness of nivolumab treatment for up to 12 months in patients with relapsed/refractory cHL. Of 304 registered patients, 288 were included in safety analyses and 282 in effectiveness analyses. There were 191 (66.3%) male patients, median age was 64.0 years, and 54 patients (18...
March 23, 2024: International Journal of Hematology
https://read.qxmd.com/read/38521410/use-of-eculizumab-in-pediatric-patients-with-high-risk-transplant-associated-thrombotic-microangiopathy-outcomes-and-risk-factors-associated-with-response-and-survival-a-retrospective-study-on-behalf-of-the-spanish-group-for-hematopoietic-transplantation-and
#24
JOURNAL ARTICLE
M I Benítez-Carabante, D Bueno, L Alonso García, I López Torija, J Marsal, Fernandez NavarroJM, M L Uria Oficialdegui, M Panesso, B Molina, C Beléndez Bieler, P Palomo, A Pérez Martínez, C Diaz-de-Heredia
INTRODUCTION: Transplant-associated thrombotic microangiopathy (TA-TMA) is associated with high morbidity and mortality. Although with the introduction of eculizumab the survival has significantly improved, there is still a need for improvement, especially in high-risk patients. OBJECTIVES: This study aims to describe the results obtained with eculizumab in a pediatric cohort with the attempt to define which risk factors could determine the response to treatment...
March 21, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38520796/eltrombopag-treatment-in-thrombocytopenia-following-hematopoietic-stem-cell-transplantation-a-multicenter-real-world-experience
#25
JOURNAL ARTICLE
Ebru Kilic Gunes, Sureyya Yigit Kaya, Fatih Yaman, Mustafa Kemal Yeniay, Kurtulus Vural, Melda Comert, Omur Gokmen Sevindik, Neslihan Andic, Simten Dagdas, Ilknur Nizam Ozen, Leylagul Kaynar, Filiz Yavasoglu, Gulsum Ozet, Volkan Karakus, Meltem Ayli
INTRODUCTION: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this multicenter and retrospective study, we aim to present our multi-center experience of Eltrombopag treatment in patients with isolated thrombocytopenia following HSCT. MATERIAL-METHOD: A total of 73 patients from 5 centers who underwent autologous or allogeneic stem cell transplantation, had no primary disease relapse, all of whom had neutrophil engraftment, complete chimerism, and who were diagnosed with Prolonged Isolated Thrombocytopenia (PIT) or Secondary Failure Of Platelet Recovery (SFPR) were included in the study...
March 15, 2024: Leukemia Research
https://read.qxmd.com/read/38518827/prior-cytomegalovirus-reactivation-may-lead-to-worse-bacterial-bloodstream-infection-outcomes-in-hsct-patients
#26
JOURNAL ARTICLE
Shanshan Li, Yang Xiao, Mei Jia
BACKGROUND: Cytomegalovirus (CMV) reactivation is common after transplantation, and may further augment natural killer (NK) cell activity, which has a protective role through both innate and adaptive immune responses. Bacterial bloodstream infections (BBSIs) are a common cause of morbidity and mortality in patients following allo-HSCT. Therefore, we hypothesized that CMV reactivation might play a role in the outcomes of patients with BBSI after allo-HSCT. OBJECTIVES: We investigated the role of CMV reactivation in the clinical outcomes of patients with BBSI after allo-HSCT...
March 20, 2024: Transplant Immunology
https://read.qxmd.com/read/38518064/lessons-learned-from-ocular-graft-versus-host-disease-an-ocular-surface-inflammatory-disease-of-known-time-of-onset
#27
JOURNAL ARTICLE
Manuel E Quiroga-Garza, Raul E Ruiz-Lozano, Luis A Rodriguez-Gutierrez, Ali Khodor, Symon Ma, Seitaro Komai, Karim Mohamed-Noriega, Victor L Perez
The ocular surface inflammatory disorders (OSIDs) comprise a group of conditions characterized by persistent inflammation of the ocular surface and adnexal tissues. Systemic autoimmune diseases and hypersensitivity reactions cause them, and, if left untreated, can result in severe inflammatory dry eye, corneal damage, and vision loss. Ocular graft-versus-host disease (oGVHD) forms part of the ocular surface inflammatory disease umbrella. It is a condition occurring after allogeneic hematopoietic stem cell or bone marrow transplantation, usually in chronic graft-versus-host disease...
March 22, 2024: Eye & Contact Lens
https://read.qxmd.com/read/38517548/secondary-solid-malignancies-and-precancerous-lesions-after-allogeneic-hematopoietic-stem-cell-transplantation-using-non-total-body-irradiation-based-conditioning-in-acute-myeloid-leukemia
#28
JOURNAL ARTICLE
Gruber Isabella, Appel Katharina, Edinger Matthias, Koelbl Oliver, Wolff Daniel
INTRODUCTION: Long-term survivors have an increased risk of developing secondary solid malignancies (SSMs) after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) with graft-versus-host disease (GVHD) potentially modulating these risks. METHODS: This retrospective study analyzed the cumulative incidences of SSMs after chemotherapy-based conditioning for allo-HSCT patients with acute myeloid leukemia (n = 266) transplanted at the University Hospital Regensburg between 1999 and 2016...
March 22, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38517255/effect-of-allogeneic-hematopoietic-stem-cell-transplantation-on-sickle-cell-disease-related-organ-complications-a-systematic-review-and-meta-analysis
#29
REVIEW
Elisabeth Dovern, Mesire Aydin, Michael R DeBaun, Komeil Alizade, Bart J Biemond, Erfan Nur
Sickle cell disease (SCD)-related organ complications are a major cause of morbidity and mortality in patients with SCD. We sought to assess whether hematopoietic stem cell transplantation (HSCT) stabilizes, attenuates, or exacerbates organ decline. We performed a systematic review and meta-analysis of trials investigating organ function before and after HSCT in patients with SCD. We searched MEDLINE/PubMed and EMBASE up to September 21, 2023. Continuous data were expressed as standardized mean difference (SMD) and pooled in a weighted inverse-variance random-effects model; binomial data were expressed as risk ratio (RR) using the Mantel-Haenszel random-effects meta-analyses...
March 22, 2024: American Journal of Hematology
https://read.qxmd.com/read/38516755/comparable-cd8-t-cell-responses-to-sars-cov-2-vaccination-in-single-cell-transcriptomics-of-recently-allogeneic-transplanted-patients-and-healthy-individuals
#30
JOURNAL ARTICLE
Eva Tranter, Marco Frentsch, Marie Luise Hütter-Krönke, Giang Lam Vuong, David Busch, Lucie Loyal, Larissa Henze, Stanislav Rosnev, Igor-Wolfgang Blau, Andreas Thiel, Dieter Beule, Lars Bullinger, Benedikt Obermayer, Il-Kang Na
Despite extensive research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination responses in healthy individuals, there is comparatively little known beyond antibody titers and T-cell responses in the vulnerable cohort of patients after allogeneic hematopoietic stem cell transplantation (ASCT). In this study, we assessed the serological response and performed longitudinal multimodal analyses including T-cell functionality and single-cell RNA sequencing combined with T cell receptor (TCR)/B cell receptor (BCR) profiling in the context of BNT162b2 vaccination in ASCT patients...
March 2024: Journal of Medical Virology
https://read.qxmd.com/read/38516258/nature-based-virtual-reality-intervention-to-manage-stress-in-family-caregivers-of-allogeneic-hematopoietic-stem-cell-transplant-recipients-a-two-phase-pilot-study-protocol
#31
JOURNAL ARTICLE
Lena J Lee, Elisa H Son, Nicole Farmer, Chantal Gerrard, Ralph Thadeus Tuason, Li Yang, Julie Kohn-Godbout, Cory Stephens, Eun-Shim Nahm, Leslie Smith, Steve Risch, Gwenyth R Wallen
UNLABELLED: Millions of family members and/or friends in the U.S. serve as unpaid caregivers for individuals with chronic conditions, such as cancer. Caregiving for someone undergoing an intense allogeneic hematopoietic stem cell transplant (HSCT) is particularly demanding, with accompanying physical and psychological stress. Increased stress and stress-related symptoms could make it difficult for caregivers to fulfill their roles and could negatively impact the health status and quality of life of themselves and the recipients...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38514025/fatal-outcome-of-bk-virus-encephalitis-in-an-allogeneic-stem-cell-transplantation-recipient
#32
Kyosuke Yamaguchi, Hisashi Yamamoto, Koji Izutsu, Mitsuhiro Yuasa, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Shuichi Taniguchi
BK virus (BKV) encephalitis is a rare complication after hematopoietic stem cell transplantation (HSCT). A 43-year-old woman with recurrent follicular lymphoma after autologous HSCT received allogeneic bone marrow transplantation from a human leukocyte antigen-matched related donor. Neutrophil engraftment was achieved on post-transplant day 13. Memory loss and noncooperative attitude toward the medical staff were observed on day 16, and her mental status worsened progressively. Magnetic resonance imaging (MRI) showed nonspecific findings on day 19; however, cerebrospinal fluid (CSF) analysis including real-time polymerase chain reaction on day 20 revealed elevated levels of BKV 4...
March 19, 2024: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://read.qxmd.com/read/38513813/predictors-of-cytomegalovirus-reactivation-after-allogeneic-hematopoietic-cell-transplantation-insights-from-a-real-world-experience
#33
JOURNAL ARTICLE
Matthew McGuirk, Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Atif Khan, Polina Bellman, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Forat Lutfi, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, Chelsea Gorsline, Dennis Matthew Shoemaker, Al-Ola Abdallah, Leyla Shune, Sunil H Abhyankar, Anurag K Singh, Joseph P McGuirk, Muhammad Umair Mushtaq
BACKGROUND: We aimed to investigate factors associated with cytomegalovirus (CMV) viremia and CMV disease and its impact on post-transplant outcomes including overall survival (OS) following allogeneic hematopoietic stem cell transplantation (Allo-SCT). METHODS: We conducted a single-center retrospective study including 452 Allo-SCT recipients (matched unrelated donor, MUD 61%; haploidentical, haplo 39%) from 2016 to 2021. Data were analyzed using SPSS v28. Descriptive (chi-square and t-test), Kaplan-Meier and regression analyses were conducted...
March 19, 2024: Transplant Immunology
https://read.qxmd.com/read/38511806/covid-19-in-hematopoietic-stem-cell-transplant-recipients-during-three-years-of-the-pandemic-a-multicenter-study-in-brazil
#34
JOURNAL ARTICLE
Bruno Azevedo Randi, Hermes Ryoiti Higashino, Vinícius Ponzio da Silva, Matias Chiarastelli Salomão, Antonio Carlos Campos Pignatari, Edson Abdala, Fabiana Vasques, Celso Arrais Rodrigues da Silva, Roberto Luiz da Silva, Carolina Dos Santos Lazari, José Eduardo Levi, Erick Menezes Xavier, Marina Farrel Côrtes, Alessandra Luna-Muschi, Vanderson Rocha, Silvia Figueiredo Costa
Hematopoietic stem cell transplant (HSCT) recipients are at -increased risk for severe COVID-19. The aim of this study was to evaluate the burden of COVID-19 in a cohort of HSCT recipients. This retrospective study evaluated a cohort of adult hospitalized HSCT recipients diagnosed with COVID-19 in two large hospitals in São Paulo, Brazil post-HSCT, from January 2020 to June 2022. The primary outcome was all-cause mortality. Of 49 cases, 63.2% were male with a median age of 47 years. Allogeneic-HSCT (51...
2024: Revista do Instituto de Medicina Tropical de São Paulo
https://read.qxmd.com/read/38510239/remission-of-relapsed-refractory-classical-hodgkin-lymphoma-induced-by-brentuximab-vedotin-and-pembrolizumab-combination-after-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#35
Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents have demonstrated clinical activity with durable responses in relapsed/refractory (r/r) HL. However, patients with a history of allo-HSCT were frequently excluded from clinical trials due to concerns about the risk of graft-versus-host disease (GVHD)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38509389/impact-of-bk-polyomavirus-viremia-on-the-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation
#36
JOURNAL ARTICLE
Yoshihiro Umezawa, Kota Yoshifuji, Keisuke Tanaka, Ayako Nogami, Katsutoshi Nagano, Ayako Tsuji, Toshikage Nagao, Masahide Yamamoto, Michiko Kajiwara, Shuji Tohda, Takehiko Mori
Although it is known that BK polyomavirus (BKPyV) causes hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT), the clinical significance of BKPyV viremia has not been fully evaluated. We retrospectively analyzed the results of quantitative polymerase chain reaction (PCR) evaluations for detecting BKPyV in the whole blood samples of patients undergoing allogeneic HSCT during the period from January 2010 to June 2020 at a single institute, Tokyo Medical and Dental University...
March 21, 2024: Annals of Hematology
https://read.qxmd.com/read/38509104/association-between-oral-and-fecal-microbiome-dysbiosis-and-treatment-complications-in-pediatric-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#37
JOURNAL ARTICLE
M Faraci, C Bonaretti, G Dell'Orso, F Pierri, S Giardino, F Angiero, S Blasi, G Farronato, E Di Marco, A Trevisiol, E Olcese, L Rufino, M Squillario, R Biassoni
The oral and gastrointestinal mucosae represent the main targets of the toxic effect of chemo and/or radiotherapy administered during the conditioning regimen before hematopoietic stem cell transplant (HSCT). These harmful consequences and the immunological complications that may occur after the transplant (such as Graft versus Host Disease, GvHD) are responsible for the clinical symptoms associated with mucositis during the aplasia phase, like pain, nausea, vomiting, and diarrhea. These toxicities could play a critical role in the oral and gastrointestinal microbiomes during the post-transplant phase, and the degree of microbial dysbiosis and dysregulation among different bacterial species could also be crucial in intestinal mucosa homeostasis, altering the host's innate and adaptive immune responses and favoring abnormal immune responses responsible for the occurrence of GvHD...
March 20, 2024: Scientific Reports
https://read.qxmd.com/read/38506145/letermovir-use-may-impact-on-the-cytomegalovirus-dna-fragmentation-profile-in-plasma-from-allogeneic-hematopoietic-stem-cell-transplant-recipients
#38
JOURNAL ARTICLE
Estela Giménez, Roberto Gozalbo-Rovira, Eliseo Albert, José Luis Piñana, Carlos Solano, David Navarro
Cytomegalovirus (CMV) DNA in plasma is mainly unprotected and highly fragmented. The size of the amplicon largely explains the variation in CMV DNA loads quantified across PCR platforms. In this proof-of-concept study, we assessed whether the CMV DNA fragmentation profile may vary across allogeneic hematopoietic stem cell transplant recipients (allo-SCT), within the same patient over time, or is affected by letermovir (LMV) use. A total of 52 plasma specimens from 14 nonconsecutive allo-SCT recipients were included...
March 2024: Journal of Medical Virology
https://read.qxmd.com/read/38505288/ursodeoxycholic-acid-does-not-reduce-sars-cov-2-infection-in-newly-allogeneic-hematopoietic-stem-cell-transplantation-recipients-a-prospective-niche-cohort
#39
JOURNAL ARTICLE
Hongye Gao, Jiali Wang, Xinhui Zheng, Xiaolei Pei, Yawei Zheng, Weihua Zhai, Rongli Zhang, Xin Chen, Qiaoling Ma, Jialin Wei, Donglin Yang, Aiming Pang, Yi He, Sizhou Feng, Yigeng Cao, Erlie Jiang
INTRODUCTION: Retrospective studies have suggested that Ursodeoxycholic Acid (UDCA) provide a protective effect against SARS-CoV-2 infection, particularly in patients with liver disease. However, it is uncertain whether this finding can be extended to the allogeneic hematopoietic stem cell transplantation (allo-HSCT) cohort. Therefore, we aim to examine the protective potential of UDCA against SARS-CoV-2 infection in recently received allo-HSCT patients. METHODS: During the initial Omicron variant wave in China (December 2022 to February 2023), we conducted a prospective observational study involving 91 hospitalized patients who had undergone allo-HSCT within the previous 6 months as part of the National Longitudinal Cohort of Hematological Diseases (NICHE)...
2024: Frontiers in Cellular and Infection Microbiology
https://read.qxmd.com/read/38503942/allogeneic-hematopoietic-stem-cell-transplantation-for-patients-with-richter-transformation-a-retrospective-study-on-behalf-of-the-chronic-malignancies-working-party-of-the-ebmt
#40
JOURNAL ARTICLE
Romain Guièze, Diderik-Jan Eikema, Linda Koster, Johannes Schetelig, Henrik Sengeloev, Jakob Passweg, Jürgen Finke, Mutlu Arat, Annoek E C Broers, Friedrich Stölzel, Jenny Byrne, Cristina Castilla-Llorente, Peter Dreger, Matthias Eder, Tobias Gedde-Dahl, Nicolaus Kröger, Josep Maria Ribera Santasusana, Deborah Richardson, Alessandro Rambaldi, Lucrecia Yañez, Michel Van Gelder, Joanna Drozd-Sokolowska, Kavita Raj, Ibrahim Yakoub-Agha, Olivier Tournilhac, Donal P McLornan
Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells...
March 19, 2024: Bone Marrow Transplantation
keyword
keyword
166555
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.